Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 19/20 | 0.56 |
| ▸ | WDR77 | Q9BQA1 | 19/20 | 0.56 |
| ▸ | ADK | P55263 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12150861 | 1.00 | PRMT5 (0.56) | PRMT5WDR77ADK | |
| SCHEMBL12154578 | 1.00 | PRMT5 (0.56) | PRMT5WDR77ADK | |
| SCHEMBL31228240 | 0.87 | PRMT5 (0.52) | PRMT5WDR77ADK | |
| SCHEMBL16198958 | 0.85 | PRMT5 (0.51) | PRMT5WDR77ADK | |
| SCHEMBL12150863 | 0.79 | PRMT5 (0.48) | PRMT5WDR77ADK | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL18661674 | 0.79 | ADORA2A (0.67) | PRMT5WDR77ADK | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL14081715 | 0.79 | ADORA2A (0.67) | PRMT5WDR77ADK | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL731022 | 0.79 | ADORA2A (0.67) | PRMT5WDR77ADK | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL15093204 | 0.79 | ADORA2A (0.67) | PRMT5WDR77ADK | |
| Beta-2'-C-Methyl-7-Deaza-Adenosine SCHEMBL13055908 | 0.79 | ADORA2A (0.67) | PRMT5WDR77ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275912-A1 | Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase | MERCK SHARP & DOHME CORP. | 2007-11-29 | — | — | US | claimed |
| EP-1355916-B1 | NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE | MERCK & CO INC (US) | 2007-01-10 | — | — | EP | claimed |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN | 2005-12-08 | — | — | US | claimed |
| US-6777395-B2 | VIRICIDES | MERCK & CO., INC. | 2004-08-17 | — | — | US | claimed |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN (US) | 2004-04-15 | — | — | US | claimed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | claimed |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2002-10-10 | — | — | US | claimed |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
| EP-2953461-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-2953462-B1 | TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C | MERCK SHARP & DOHME (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-2780026-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | MERCK SHARP & DOHME LLC | 2004-06-10 | — | — | US | disclosed |
| CN-1498221-A | Nucleoside derivatives as inhibitors of RNA-dependent PNA viral polymerase | — | 2004-05-19 | — | — | CN | disclosed |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | BHAT BALKRISHEN (US) | 2004-04-15 | — | — | US | disclosed |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2004-04-08 | — | — | US | disclosed |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20040014108-A1 | Oligonucleotides having modified nucleoside units | ISIS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | MERCK SHARP & DOHME LLC | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | PRMT5 2225/4885WDR77 2310/4885ADK 2394/4885 |
| US-20040067901-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | PRMT5 436/4885WDR77 1478/4885ADK 239/4885 |
| US-20040014108-A1 | Oligonucleotides having modified nucleoside units | RNASEH1, RNASE1, RNASEL | PRMT5 2966/4885WDR77 1841/4885ADK 454/4885 |
| US-20040014957-A1 | Oligonucleotides having modified nucleoside units | RNASE1, RNASEH1, RNASEL | PRMT5 3154/4885WDR77 1648/4885ADK 325/4885 |
| US-20040110717-A1 | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase | NSUN2, NSUN3, POLRMT | PRMT5 352/4885WDR77 1658/4885ADK 215/4885 |
| US-20040072788-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | PRMT5 436/4885WDR77 1478/4885ADK 239/4885 |
| US-20050272676-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | PRMT5 436/4885WDR77 1478/4885ADK 239/4885 |
| US-20020147160-A1 | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | PRMT5 436/4885WDR77 1478/4885ADK 239/4885 |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | HAVCR2, HCCS, EIF2AK2 | PRMT5 2225/4885WDR77 2310/4885ADK 2394/4885 |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | PRMT5 2225/4885WDR77 2310/4885ADK 2394/4885 |
| US-20070275912-A1 | Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase | NSUN2, NSUN3, POLRMT | PRMT5 436/4885WDR77 1478/4885ADK 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.